6939 Stock Overview
A contract research organization, provides biological testing services in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
TFBS Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$38.00 |
| 52 Week High | NT$53.00 |
| 52 Week Low | NT$36.10 |
| Beta | 0 |
| 11 Month Change | 0.53% |
| 3 Month Change | 0% |
| 1 Year Change | -11.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6939 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | -0.5% | -2.3% | -0.8% |
| 1Y | -11.6% | -13.3% | 29.0% |
Return vs Industry: 6939 exceeded the TW Life Sciences industry which returned -13.3% over the past year.
Return vs Market: 6939 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 6939 volatility | |
|---|---|
| 6939 Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 4.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6939 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6939's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Tatung Yuan | www.tfbsbio.com |
TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.
TFBS Bioscience Inc. Fundamentals Summary
| 6939 fundamental statistics | |
|---|---|
| Market cap | NT$1.32b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6939 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6939 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6939 perform over the long term?
See historical performance and comparison